Literature DB >> 10979975

Maintenance of retinoic acid receptor alpha pools by granulocyte colony-stimulating factor and lithium chloride in all-trans retinoic acid-treated WEHI-3B leukemia cells: relevance to the synergistic induction of terminal differentiation.

R A Finch1, J Li, T C Chou, A C Sartorelli.   

Abstract

Previous studies have demonstrated that combinations of all-trans retinoic acid (ATRA) with either granulocyte-colony stimulating factor (G-CSF) or lithium chloride (LiCl) produced synergistic terminal differentiation of WEHI-3B myelomonocytic leukemia (D(+)) cells. It was found that steady-state retinoic acid receptor alpha (RARalpha) protein levels were markedly reduced in these cells after exposure to ATRA. Because the presence of receptors for a hormone ligand is required for its action, differentiation therapy with ATRA may be self-limiting. The combination of G-CSF with ATRA significantly attenuated the loss of RARalpha protein, and synergistic terminal differentiation occurred. LiCl was more effective than G-CSF in preserving RARalpha pools and synergized with ATRA more strongly than G-CSF. These findings suggested that the prevention of RARalpha protein loss by G-CSF or LiCl in ATRA-treated cells functioned to extend the differentiation response to the retinoid and was responsible, at least in part, for the observed synergism. D(+) cells transfected with an expression plasmid containing RARalpha cDNA had a 6- to 8-fold increase in steady-state RARalpha mRNA compared with vector-transfected cells and showed a 2- to 3-fold increase in RARalpha protein. ATRA caused a reduction, but not a complete loss, of RARalpha protein in these transfectants, which were considerably more responsive than parental D(+) cells to ATRA as a single agent, supporting the concept that the protection of RARalpha pools results in a heightened differentiation response to ATRA.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10979975

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Cooperative antitumor effects of vitamin D3 derivatives and rosemary preparations in a mouse model of myeloid leukemia.

Authors:  Hagar Sharabani; Eugene Izumchenko; Qing Wang; Rita Kreinin; Michael Steiner; Zeev Barvish; Michael Kafka; Yoav Sharoni; Joseph Levy; Milan Uskokovic; George P Studzinski; Michael Danilenko
Journal:  Int J Cancer       Date:  2006-06-15       Impact factor: 7.396

Review 2.  Molecular mechanisms of leukemia-associated protein degradation.

Authors:  Ying-Li Wu; Hu-Chen Zhou; Guo-Qiang Chen
Journal:  Front Med China       Date:  2010-11-19

3.  Induction of autophagy is a key component of all-trans-retinoic acid-induced differentiation in leukemia cells and a potential target for pharmacologic modulation.

Authors:  Nina Orfali; Tracey R O'Donovan; Michelle J Nyhan; Adrian Britschgi; Mario P Tschan; Mary R Cahill; Nigel P Mongan; Lorraine J Gudas; Sharon L McKenna
Journal:  Exp Hematol       Date:  2015-05-16       Impact factor: 3.084

4.  Inhibition of all-trans retinoic acid-induced granulocytic differentiation of WEHI-3B D+ cells by forced expression of SCL (TAL1) and GATA-1.

Authors:  Kimiko Ishiguro; Anna M Rice; Kevin P Rice; Alan C Sartorelli
Journal:  Leuk Res       Date:  2009-02-20       Impact factor: 3.156

5.  Oridonin stabilizes retinoic acid receptor alpha through ROS-activated NF-κB signaling.

Authors:  Yang Cao; Wei Wei; Nan Zhang; Qing Yu; Wen-Bin Xu; Wen-Jun Yu; Guo-Qiang Chen; Ying-Li Wu; Hua Yan
Journal:  BMC Cancer       Date:  2015-04-10       Impact factor: 4.430

6.  Retinoid differentiation therapy for common types of acute myeloid leukemia.

Authors:  Geoffrey Brown; Philip Hughes
Journal:  Leuk Res Treatment       Date:  2012-06-12

7.  2-Bromopalmitate targets retinoic acid receptor alpha and overcomes all-trans retinoic acid resistance of acute promyelocytic leukemia.

Authors:  Ying Lu; Jin-Song Yan; Li Xia; Kang Qin; Qian-Qian Yin; Hong-Tao Xu; Meng-Qing Gao; Xiao-Ning Qu; Yu-Ting Sun; Guo-Qiang Chen
Journal:  Haematologica       Date:  2018-08-03       Impact factor: 9.941

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.